127 related articles for article (PubMed ID: 29220097)
21. Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications.
Goldberg H; Zandbank J; Kent V; Leonov-Polak M; Livoff A; Chernihovsky A; Guindy M; Evron E
Eur J Surg Oncol; 2017 Aug; 43(8):1415-1420. PubMed ID: 28526187
[TBL] [Abstract][Full Text] [Related]
22. Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.
Rubio IT; Aznar F; Lirola J; Peg V; Xercavins J
Ann Surg Oncol; 2010 Jan; 17(1):235-9. PubMed ID: 19777186
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
24. Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements.
Nagashima T; Sakakibara M; Kadowaki M; Suzuki TH; Yokomizo J; Ohki Y; Miyoshi T; Kazama T; Nakatani Y; Miyazaki M
Acta Radiol; 2011 Apr; 52(3):241-6. PubMed ID: 21498357
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
26. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
27. Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter.
Piotrzkowska-Wróblewska H; Dobruch-Sobczak K; Klimonda Z; Karwat P; Roszkowska-Purska K; Gumowska M; Litniewski J
PLoS One; 2019; 14(3):e0213749. PubMed ID: 30870478
[TBL] [Abstract][Full Text] [Related]
28. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer.
Park S; Lee JE; Paik HJ; Ryu JM; Bae SY; Lee SK; Kim SW; Nam SJ
Clin Breast Cancer; 2017 Feb; 17(1):e19-e29. PubMed ID: 27495997
[TBL] [Abstract][Full Text] [Related]
30. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
32. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
33. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy.
Miller M; Ottesen RA; Niland JC; Kruper L; Chen SL; Vito C
Ann Surg Oncol; 2014 Oct; 21(10):3317-23. PubMed ID: 25059788
[TBL] [Abstract][Full Text] [Related]
34. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy.
Nogi H; Uchida K; Mimoto R; Kamio M; Shioya H; Toriumi Y; Suzuki M; Nagasaki E; Kobayashi T; Takeyama H
Clin Breast Cancer; 2017 Dec; 17(8):644-649. PubMed ID: 28601382
[TBL] [Abstract][Full Text] [Related]
36. Hypervascularity Predicts Complete Pathologic Response to Chemotherapy and Late Outcomes in Breast Cancer.
Bufi E; Belli P; Di Matteo M; Giuliani M; Tumino M; Rinaldi P; Nardone L; Franceschini G; Mulé A; Bonomo L
Clin Breast Cancer; 2016 Dec; 16(6):e193-e201. PubMed ID: 27431459
[TBL] [Abstract][Full Text] [Related]
37. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine needle aspiration.
Yu Y; Cui N; Li HY; Wu YM; Xu L; Fang M; Sheng Y
BMC Cancer; 2016 Oct; 16(1):808. PubMed ID: 27756234
[TBL] [Abstract][Full Text] [Related]
38. Axillary staging in the neoadjuvant setting.
Chung A; Giuliano A
Ann Surg Oncol; 2010 Sep; 17(9):2401-10. PubMed ID: 20229221
[TBL] [Abstract][Full Text] [Related]
39. One-Step Nucleic Acid Amplification Assay for Detection of Axillary Lymph Node Metastases in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Takamoto K; Shimazu K; Naoi Y; Shimomura A; Shimoda M; Kagara N; Kim SJ; Tamaki Y; Noguchi S
Ann Surg Oncol; 2016 Jan; 23(1):78-86. PubMed ID: 26152274
[TBL] [Abstract][Full Text] [Related]
40. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]